Dendreon Corporation
Biotech Company
Stock symbol: "DNDN"
How much do you think Dendreon is worth? Vote now!
My personal Research on Dendreon Corporation.
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics that harness the immune system to fight cancer. Its product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. The company's product candidates include Provenge (sipuleucel-T), an active cellular immunotherapy that is in FDA priority review status for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), which has completed phase 1 clinical trials for the treatment of breast, ovarian, and colon cancers. Dendreon also has various products in preclinical studies, which include Trp-p8 for the treatment of lung, breast, prostate, and colon cancers; CEA for the treatment of breast, lung, and colon cancers; CA-9 (MN) for the treatment of kidney, colon, and cervical cancers; and Anti-Serine Protease for the treatment of multiple cancers. The company has collaborative agreements with Genentech, Inc. for the preclinical research, clinical development, and commercialization of products derived from trp-p8, an ion channel found in prostate cancer cells; and with Amgen Fremont, Inc. for the discovery, development, and commercialization of human monoclonal antibodies against a membrane-bound serine protease. Dendreon, formerly known as Activated Cell Therapy, Inc., was founded in 1992. The company is based in Seattle, Washington.
- Amazing Prophets with Lots of Profits in Dendreon
- Dendreon put options price went up!
- Sirius Satellite could be a buyout candidate!
- Bank of America acquire Lasalle Bank for $21 Billiions
- Full coverage on Dendreon and Provenge
- Learn more about Provenge.
- Who are the true owners of Denderon?
- Will Warren Buffet invest in Denderon?
- CEO of Dendeon Sold 202,090 shares, he's not confident about Dendreon!
- WARNING: Investing in a drug that the FDA has not approve is Gambling.
- Fundamental Analysis on Denderon
- Dendreon Announces FDA Advisory Committee Reviewed Provenge ® for Hormone Refractory Prostate Cancer
Warning: 1pennystock.com does not offer stock recommendations in any way. You have to do your own research before you buy or sell any securities. This free report is for entertainment or education purposes only. Please consult your stock broker before you buy or sell any securities.